BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 7281240)

  • 1. DTIC and actinomycin D with and without C. parvum immunotherapy in advanced malignant melanoma.
    Halpern J; Catane R; Biran S; Fuks Z
    Tumori; 1981; 67(3):215-7. PubMed ID: 7281240
    [No Abstract]   [Full Text] [Related]  

  • 2. Actinomycin-D plus 5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamine (DTIC) with or without intravenous Corynebacterium parvum in metastatic malignant melanoma.
    Robidoux A; Gutterman JU; Bodey GP; Hersh EM
    Cancer; 1982 Jun; 49(11):2246-51. PubMed ID: 7042068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemoimmunotherapy (DTIC and Corynebacterium parvum) for disseminated malignant melanoma.
    Karakousis CP; Didolkar MS; Han T
    Cancer Treat Rep; 1981; 65(9-10):925-6. PubMed ID: 7273032
    [No Abstract]   [Full Text] [Related]  

  • 4. A trial of imidazole carboxamide and corynebacterium parvum in disseminated melanoma: clinical and immunologic results.
    Clunie GJ; Gough IR; Dury M; Furnival CM; Bolton PM
    Cancer; 1980 Aug; 46(3):475-9. PubMed ID: 6994866
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized study of Corynebacterium parvum adjuvant therapy following surgery for (stage II) malignant melanoma.
    Thatcher N; Mene A; Banerjee SS; Craig P; Gleave N; Orton C
    Br J Surg; 1986 Feb; 73(2):111-5. PubMed ID: 3512025
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemoimmunotherapy (DTIC and Corynebacterium parvum) as adjuvant treatment in malignant melanoma.
    Karakousis CP; Didolkar MS; Lopez R; Baffi R; Moore R; Holyoke ED
    Cancer Treat Rep; 1979; 63(11-12):1739-43. PubMed ID: 393377
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inefficacy of sc Corynebacterium parvum in stage I malignant melanoma: preliminary results of a single-institution pilot study.
    Murray JL; Ishmael DR; Bottomley RH; Grozea PN; Lee ET
    Cancer Treat Rep; 1983 Feb; 67(2):191-2. PubMed ID: 6825130
    [No Abstract]   [Full Text] [Related]  

  • 8. Bacillus Calmette-Guérin immunotherapy in combination with DTIC (NSC-45388) for the treatment of malignant melanoma.
    Gutterman JU; Mavligit GM; Reed R; Burgess MA; Gottlieb J; Hersh EM
    Cancer Treat Rep; 1976 Feb; 60(2):177-82. PubMed ID: 769970
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Controlled study with imidazole carboxamide (DTIC), DTIC + bacillus Calmette-Guérin (BCG), and DTIC + corynebacterium parvum in advanced malignant melanoma. W.H.O. Collaborating Centres for Evaluation of Methods of Diagnosis and Treatment of Melanoma.
    Tumori; 1984 Feb; 70(1):41-8. PubMed ID: 6369694
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemoimmunotherapy for meningeal melanocytoma of the thoracic spinal cord. Report of a case.
    Verma DS; Spitzer G; Legha S; McCredie KB
    JAMA; 1979 Nov; 242(22):2435-6. PubMed ID: 490860
    [No Abstract]   [Full Text] [Related]  

  • 11. The role of immunotherapy in the management of patients with malignant melanoma.
    Goodnight JE; Morton DL
    World J Surg; 1979 Jul; 3(3):309-20. PubMed ID: 382645
    [No Abstract]   [Full Text] [Related]  

  • 12. Cyclophosphamide plus 5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamide (DTIC) with or without Corynebacterium parvum in metastatic malignant melanoma.
    Presant CA; Bartolucci AA; Smalley RV; Vogler WR
    Cancer; 1979 Sep; 44(3):899-905. PubMed ID: 383276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Malignant angioendothelioma--effect of immunotherapy with Corynebacterium parvum.
    Tan SG; Cotterill JA; Roberts MM; Cunliffe WJ
    Acta Derm Venereol; 1978; 58(6):551-3. PubMed ID: 83086
    [No Abstract]   [Full Text] [Related]  

  • 14. Surgical adjuvant therapy of malignant melanoma with corynebacterium parvum.
    Hilal EY; Pinsky CM; Hirshaut Y; Wanebo HJ; Hansen JA; Braun DW; Fortner JG; Oettgen HF
    Cancer; 1981 Jul; 48(2):245-51. PubMed ID: 7016302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemoimmunotherapy in disseminated melanoma and colorectal carcinoma.
    Gough IR; Bolton PM; Clunie GJ; Burnett W
    Aust N Z J Surg; 1978 Jun; 48(3):296-300. PubMed ID: 281221
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjuvant therapy of cutaneous malignant melanoma: a critical review.
    Koh HK; Sober AJ; Harmon DC; Lew RA; Carey RW
    Med Pediatr Oncol; 1985; 13(5):244-60. PubMed ID: 3897817
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Corynebacterium parvum followed by chemotherapy (actinomycin D and DTIC) compared with chemotherapy alone for metastatic malignant melanoma.
    Thatcher N; Wagstaff J; Mene A; Smith D; Orton C; Craig P
    Eur J Cancer Clin Oncol; 1986 Aug; 22(8):1009-14. PubMed ID: 3770045
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of adjuvant therapy in melanoma management.
    Barth A; Morton DL
    Cancer; 1995 Jan; 75(2 Suppl):726-34. PubMed ID: 7805001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant therapy for malignant melanoma.
    Kaiser LR; Burk MW; Morton DL
    Surg Clin North Am; 1981 Dec; 61(6):1249-57. PubMed ID: 7313933
    [No Abstract]   [Full Text] [Related]  

  • 20. Ineffectiveness of adjuvant chemotherapy using DTIC and cyclophosphamide in patients with resectable metastatic melanoma.
    Balch CM; Murray D; Presant C; Bartolucci AA
    Surgery; 1984 Apr; 95(4):454-9. PubMed ID: 6369594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.